BMS Loss is Merck’s Gain, Biogen Takeover Speculation, & GSK’s Bioelectronics Foray

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Vertex Antes for Alpine, Regeneron Faces DOJ Scrutiny, & the Illumina Shakeup
A ProfoundBio Windfall, Amylyx Yanks Failed ALS Drug, & Verve’s Rough Patch
Boundless’ IPO, Merck’s Acceleron Win, & Moderna’s $750M Flu Vaccine Boost
Megarounds Return, AZ Buys a Radiopharma Player, & Lonza’s California Dream